Angion Biomedica Corp (ANGN)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
CEO:
Jay R. Venkatesan
Employees:
70
51 CHARLES LINDBERGH BOULEVARD, UNIONDALE, NY 11553
(415) 655-4899

Angion Biomedica Corp. focuses on the discovery, development, and commercialization of small molecule therapeutics. The company's lead product candidate is an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops a hepatocyte growth factor mimetic to treat acute organ injuries.

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 60.893 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.53
Price to Revenue1.1504 Debt to Equity0.0 EBITDA-23.659 Million
Price to Book Value0.5718 Operating Margin-82.9708 Enterprise Value-29.202 Million
Current Ratio8.469 EPS Growth0.892 Quick Ratio8.146
1 Yr BETA 1.3819 52-week High/Low 9.35 / 0.87 Profit Margin-81.4524
Operating Cash Flow Growth-125.5924 Altman Z-Score-2.601 Free Cash Flow to Firm -53.844 Million
Earnings Report2022-11-10
View SEC Filings from ANGN instead.

View recent insider trading info

Funds Holding ANGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANGN

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GOLDBERG ITZHAK

  • Director
1,687,986 2022-07-01 3

OMENN GILBERT S

  • Director
15,000 2022-06-09 1

GANZI VICTOR F

  • Director
15,000 2022-06-09 1

WILSON KAREN J

  • Director
15,000 2022-06-09 1

NISSENSON ALLEN

  • Director
15,000 2022-06-09 2

VENKATESAN JAY SEE REMARKS

  • Officer
  • Director
1,891,947 2022-05-25 6

CURHAN GREGORY S SEE REMARKS

  • Officer
100,000 2022-03-02 2

RHODES JENNIFER J SEE REMARKS

  • Officer
275,000 2022-03-02 3

NEYLAN JOHN F. SEE REMARKS

  • Officer
275,000 2022-03-02 3

LYNCH WENDY D.

  • Director
9,520 2012-10-12 0

STRUIK HENDRIK

  • Director
13,135 2012-09-28 0

MUNZENRIDER ROBERT E

  • Director
31,235 2012-06-13 0

LEHMAN GREGG OWEN PRESIDENT & CEO

  • Officer
48,478 2012-06-13 0

SHUDA SCOTT

  • Director
296,390 2010-06-21 0

YOUNG RODNEY A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
41,069 2008-09-11 0

KULLBACK WILLIAM J SVP & CHIEF FINANCIAL OFFICER

  • Officer
5,000 2008-06-27 0

JOHNSON DALE H CHIEF FINANCIAL OFFICER

  • Officer
  • Director
13,000 2007-04-18 0

EHLEN K JAMES

  • Director
0 2007-04-12 0

PENN JOHN C

  • Director
3,105 2007-04-09 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ANGION BIOMEDICA CORP ANGN 2022-10-05 22:15:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 21:45:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 21:15:04 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 20:45:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 20:15:04 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 19:45:04 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 19:15:04 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 18:45:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 18:15:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 17:45:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 17:15:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 16:45:04 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 16:15:03 UTC 0.9285 2.1415 450000
ANGION BIOMEDICA CORP ANGN 2022-10-05 15:45:03 UTC 0.9285 2.1415 400000
ANGION BIOMEDICA CORP ANGN 2022-10-05 15:15:03 UTC 0.9285 2.1415 400000
ANGION BIOMEDICA CORP ANGN 2022-10-05 14:45:03 UTC 0.9285 2.1415 400000
ANGION BIOMEDICA CORP ANGN 2022-10-05 14:15:03 UTC 0.9285 2.1415 400000
ANGION BIOMEDICA CORP ANGN 2022-10-05 13:45:03 UTC 0.9285 2.1415 400000
ANGION BIOMEDICA CORP ANGN 2022-10-05 13:15:03 UTC 0.9285 2.1415 400000
ANGION BIOMEDICA CORP ANGN 2022-10-05 12:45:03 UTC 0.9285 2.1415 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

No recent transactions

*** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

Elevate your investments